Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Solasia’s Peripheral Neuropathy Drug Fails in PIII in Colorectal Cancer Patients
Solasia Pharma said on December 15 that SP-04 (calmangafodipir), a treatment for chemotherapy-induced peripheral neuropathy, failed to meet the primary endpoint in a global PIII study enrolling colorectal cancer patients treated with mFOLFOX6 therapy.The company will conduct further analysis on…
To read the full story
Related Article
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





